Recently, combination therapy with a PD-L1 inhibitor (atezolizumab) and VEGF inhibitor (bevacizumab) demonstrated remarkable outcomes compared to sorafenib in the treatment of unresectable HCC [22]. This evidence concerns the gene CD274 and hepatocellular carcinoma.